The picture of future therapy

International Journal of Clinical Practice, Supplement

Volumn , Issue 103, 1999, Pages 45-48

  Gazzard, Brian ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

CONFERENCE PAPER; DRUG COST; DRUG POTENCY; DRUG RESEARCH; DYSLIPIDEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; INTRAVENOUS DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT FAILURE; DRUG COMBINATION; FORECASTING; REVIEW; TREATMENT REFUSAL;

DRUG THERAPY, COMBINATION; FORECASTING; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT REFUSAL;

EID: 0032585904     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Int Med 1998; 128: 1079-1100.
2. December 1998 update of treatment guidelines. http://www.hivatis.org
3. Moore RD, Keruly JC, Chaisson RE. The costs of medical care in HIV disease. (Abstract 4969) International Conference on AIDS, Vancouver 1996.
4. Deeks SG, Barditch-Crovo P, Lietman PS et al. Safety, pharmacokinetics and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998; 42: 2380-2384.
5. Pialoux G, Raffi F, Brun-Vezinet F et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine and indinavir in previously untreated HIV-1-infected patients. Trilege Study Team. N Engl J Med 1998; 339: 1269-1276.
6. Havlir DV, Marschner IC, Martin MS et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998; 339: 1261-1268.
7. Reijers MH, Weverling GJ, Jurriaans S et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998; 352: 185-190.
8. Moyle G. Antiretroviral therapy. In: Gazzard B, Ed. Chelsea & Westminster Hospital AIDS Care Handbook. Doncaster: Mediscript Ltd Medical Publisher, 1999; 285-328.
9. Carr A, Samaraas K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
10. Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12: F167-173.
11. Morales-Ramirez J, Tashima K, Hardy D et al. A Phase III, multicenter. randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 36 weeks [DMP 266-006]. 38th ICAAC, San Diego 1998.
12. Delehanty J, Wakeford C, Hulett L et al. A Phase I/ll randomized, controlled study of FTC versus 3TC in HIV-infected patients. (Abstract 16) 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999.
13. Florence E, Desmet P, Pelgrom Y et al. Iris study: ritonavir/saquinavir versus indinavir in association with NRTI: one year follow up. (Abstract 630) 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999.
14. Johnson M on behalf of the SPICE (NV15436) study group. Quadruple therapy with saquinavir-soft gelatin (SQV-SGC) capsules plus nelfinavir (NFV) versus triple therapy with either SQVSGC or NFV in patients with antiretroviral experience or high baseline viral load. (Abstract 389) 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999.
15. Gerstoft J, Kirk O, Katzenstein T et al. Saquinavir/ritonavir have better short term antiretroviral efficacy than either ritonavir or indinavir in HIV-infected antiretroviral naïve patients. OP2.6. 4th International Congress on Drug Therapy in HIV-infection, Glasgow 1998.
16. Kumar GN, Jayanti V, Lee RD et al. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolic identification. Drug Metab Dispos 1999; 27: 86-91.
17. Turner SR, Strohbach JW, Tommasi RA et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998; 41: 3467-3476.
18. Faraj A, Agrofoglio LA, Wakefield JK et al. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'triphosphate beta enantiomers of cytidine analogs. Antimicrob Agents Chemother 1994; 38: 2300-2305.
19. Little RF, Serchuck L, Lietzau J et al. Phase I adult and pediatric studies of lodenosine (F-ddA) as monotherapy and combined with stavudine and nelfinavir. (Abstract 380) 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999.
20. Rutschmann OT, Opravil M, Iten A et al. ddl + d4T +/- hydroxyurea for HIV-1 infection. (Abstract 656) 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998.
21. Lalezari J, Eron J, Carlson M et al. Safety, pharmacokinetics and antiviral activity of T-20 as a single agent in heavily pre-treated patients. (Abstract 13) 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999.
22. Barney S, Guthrie K, Davis D et al. A novel hybrid synthetic peptide inhibitor of HIV-1, SIV and HIV-2 fusion and infection in vitro. (Abstract 616) 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999.
23. Kovacs JA, Vogel S, Albert JM et al. Controlled trial of Interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335: 1350-1356.